Aegon Ltd Dossier
|
SectorFinancials IndustryInsurance - Diversified Beta (adjusted)0.88 Intrinsic Value $6.99median of 2 methodsbased on filings through 31 Dec 2025 Market Price $8.63Price as of 30 Sep 2026 OvervaluedIntrinsic value is 19% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $12.8B Enterprise Value $15.2B Shares Outstanding 1.6B diluted Next Earnings Date31 Dec 2026 Last ex-dividend15 Jun 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Aegon's first-half performance was strong: operating result increased 9% to EUR 804 million and operating capital generation increased 27% to EUR 416 million. Its official Euronext price was EUR 8.03 on August 31, compared with reported valuation equity per share of EUR 9.42. The apparent valuation support and expanded capital returns are balanced by material execution dependencies, including shareholder approval and implementation of the US redomiciliation, completion of the Aegon UK sale, and conversion to US GAAP. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$9.15 Mean target$9.88 High · most bullish analyst$10.60 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $9.1520% The downside case assumes the redomiciliation is rejected or materially delayed, the UK sale does not close around year-end 2026, or operating capital generation falls below the stated 0%-5% growth ambition. These outcomes could delay simplification, capital deployment, and the intended transition toward a US-focused insurance and retirement group. Base CaseCentral scenario $9.8850% Matches the consensus meanThe central case assumes operating result and free cash flow grow broadly in line with Aegon's approximately 5% annual ambitions, while the UK disposal and redomiciliation proceed with manageable timing or implementation friction. Capital distributions remain supported, but transition costs and execution uncertainty restrain conviction. Bull CaseUpside scenario $10.6030% The upside case assumes Aegon meets or exceeds its revised ambitions, completes the UK sale around year-end 2026, secures approval for the US redomiciliation, and sustains Transamerica's commercial momentum. Successful execution, continuing buybacks, and dividend growth above 5% could improve investor confidence. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |